Integra LifeSciences Holdings IART

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.

IART hizo una división de acciones (split) de 2:1 el 4 de enero de 2017: cada acción se convirtió en 2. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• The Motley Fool 2 oct

  Stock Market Midday, Oct. 2: Stocks Rally as Weak Jobs Data Cools Fed Rate Hike Bets

  U.S. stock markets rallied on October 2, 2026, following weaker-than-expected September employment data showing only 29,000 jobs added and unemployment rising to 4.2%. The soft labor report reduced expectations for a Federal Reserve rate hike this month from 64% to 21%, boosting investor sentiment particularly in tech and growth stocks. The Nasdaq Composite hit a record high, while the S&P 500 and Dow Jones also gained.

  

• Zacks Investment Research 1 oct

  IART vs. PEN: Which Stock Is the Better Value Option?

  In a comparison of two medical instruments sector stocks, Integra LifeSciences (IART) emerges as the better value opportunity for investors compared to Penumbra (PEN). IART has a Zacks Rank of #2 (Buy) with a forward P/E of 6.62 and Value grade of B, while PEN has a Zacks Rank of #3 (Hold) with a forward P/E of 64.18 and Value grade of D. IART's superior valuation metrics and improving earnings outlook make it the more attractive choice for value investors.

  

• Zacks Investment Research 30 sept

  Should You Continue to Hold IART Stock in Your Portfolio?

  Integra LifeSciences (IART) reported 1.6% organic growth in Specialty Surgery revenues driven by neurosurgery strength and improved supply reliability. Adjusted EPS rose 24.4% with margin expansion, and the company is ramping up Braintree production for a SurgiMend relaunch. However, elevated leverage at 4.1X and foreign exchange headwinds pressured full-year revenue guidance and financial flexibility.

  

• Zacks Investment Research 29 sept

  IART or PEN: Which Is the Better Value Stock Right Now?

  A comparison of two medical instruments companies reveals that Integra LifeSciences (IART) presents a more attractive value opportunity than Penumbra (PEN). IART has a Zacks Rank of #2 (Buy) with a forward P/E of 6.61 and Value grade of B, while PEN has a Zacks Rank of #3 (Hold) with a forward P/E of 64.35 and Value grade of D. IART's stronger earnings estimate revisions and superior valuation metrics make it the preferred choice for value investors.

  

• GlobeNewswire Inc. 28 jul

  Ultrasonic Aspirator Market Size Projected to Reach USD 376.32 Million by 2035 | SNS Insider

  The global ultrasonic aspirator market is valued at USD 194.03 million in 2025 and is projected to reach USD 376.32 million by 2035, growing at a CAGR of 6.87%. The U.S. market is expected to grow from USD 67.49 million to USD 118.90 million by 2035, driven by increasing adoption of advanced surgical technologies, rising neurosurgery procedures, and growing demand for minimally invasive surgeries. North America leads the market with 39.80% share, while Asia-Pacific registers the fastest growth at 8.83% CAGR.